Despite cancer chemotherapy has entered a new era of molecularly targeted therapeutics and some forms of cancer have been successfully treated by modern therapies, the successful treatment of cancer remains a significant challenge in the future because chemotherapy is limited by the drug resistance and adverse side effects.
6a-l were both geometrically pure and were exclusively trans (E) isomers. Thus, appropriate aryl aldehydes were reacted with inexpensive p-hydroxyacetophenone in ethanol/ KOH at 0-5°C. Upon completion, the cooled reaction mixture was poured into ice water and treated with HCl (10%) yielded the desired chalcone analogues (6a-l).
Finally, the target compounds 9a-l and 10a-l were successfully obtained via the reaction of intermediate 7 and 8 with 6a-m in the presence of K 2 CO 3 and sodium iodide in N,N-dimethylformamide (DMF) at 60°C, respectively. The products obtained were purified by column chromatography on silica gel.
The formation of 10b-azidoartemisinin (2) and 10a-azidoartemisinin (3) were confirmed by 1 H-NMR spectrum and LC-MS data. In our previous report, the stereochemistry of compound 2 had ready been determined by single crystal Xray diffraction studies.
27) The structure of compound 3 was elucidated by 1 H-NMR spectrum and LC-MS analyses. Specifically, the configuration at the C-10 position of compound 3 was assigned based on the vicinal couplings (Jϭ10.1 Hz) between protons at positions 10 and 9, indicating that the relative configuration at the positions 10 and 9 is trans.
In addition, the molecular structure of the compound 5 was established by single crystal X-ray diffraction studies. The ORTEP view of the molecular structure shows the spatial atomic positions of compound 5, as shown in Fig. 2 . The stereochemistry of compound 3 was further determined indirectly by the crystal data of compound 5, because the configuration at the C-10 was not changed when compound 3 was transformed to compound 5 via the Staudinger reduction.
The formation of two important intermediates (7, 8) were confirmed by 1 H-NMR spectral and LC-MS data, The formation of the title compounds, were evidenced by 1 H-NMR spectrum, IR, LC-MS and element analysis data, which were explained in experimental part.
Results and Discussion
Biological Evaluation All the compounds 9a-l and 10a-l were evaluated for their anti-tumor activities on human colorectal cancer cell line (HT-29), human non-smallcell lung cancer cell line (A549), human breast cancer cell line (MDA-MB-231), human cervical carcinoma cell line (HeLa) and human lung cancer cell line (H460) by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, using DHA as a control. The results expressed as IC 50 were summarized in Table 1 , and the IC 50 values are the average of at least two independent experiments.
As shown in Table 1 , most of the compounds 9a-l and 10a-l were 2.6-to 40-fold more active than the corresponding dihydroartemisinin (DHA) respectively, suggesting that the presence of a chalcone moiety enhanced their anti-tumor activities significantly toward all five cancer cell lines. In general, most of the prepared compounds showed moderate activity against MDA-MB-231, A549 and H460 cell lines with IC 50 values ranging from 0.68 to 29 mM, which were several-to tens-fold less potent than against HT-29 and HeLa cell lines respectively. The results demonstrated that the introduction of a chalcone moiety also enhanced their selectivity significantly for HT-29 and HeLa cell lines. The two key intermediates 4 and 5 with amino group at C-10 position caused only a minor improvement in anti-tumor activity against the five cancer cell lines as compared to DHA.
Turning to the effects of 9j and 9k containing heteroaromatic chalcone moiety, interestingly, the bioisosteric replacement of phenyl (9i) with a thiophene ring (9k) and furan (9j) ring decreased activity greatly against the five tumor cell lines respectively. It may be concluded that the presence of heteroaromatic ring is detrimental for the activity. The data in Table 1 demonstrated that substitution pattern on the phenyl rings linked to the b-position of the enone system affected their potency significantly. For 9a-l, in most cases, compounds (9c, d, g) bearing electron withdrawing groups (EWG) at the phenyl rings are found to be more active than compounds attached electron releasing groups (9h, l) with the exception of 3,4,5-trimethoxy derivative 9b, with IC 50 values 0.70-1.9 mM. The fluoro substituent (9a, e) had comparable anti-tumor activity with the unsubstituted analogue 9i. Specifically with the mono-halogen substituted derivatives (9e, f), activity increased in the following order: Cl (9f)ϾF (9e). Insertion of a second chlorine atom, to yield the 2,6-dichloro derivative 9g, resulted in about a fourfold increase in activity as compared with 9f. Ignoring the derivative with a 3-MeO (9h) and 3,4-OCH 2 O-(9l), the greatest enhancement of activity occurred with the bulkier substituents, 3-CF 3 (9d) and 4-CF 3 O (9c).
Regarding the anti-tumor activities of 10a-l, bearing a same molecular structure but only different C-10 stereochemistry, showed few differences in inhibitory effect against five cell lines as compared with 9a-l. Among them, the 10c, d and g had the best activities toward the five cell lines, which further proved that it was beneficial for enhancing their anti-tumor activities when compounds with bulkier and EWG group on the phenyl ring. The replacement of phenyl with hetero-aryl group would result in a decrease of antitumor activity and hence they aren't ideally suited for further modifications.
Conclusion
In summary, two novel series of hybrid artemisinin derivatives conjugated with chalcone moieties were designed and synthesized based on the hybrid strategy. The structures were confirmed by elemental analyses, spectrometry and single crystal X-ray analysis. Through anti-tumor activity screening against five cell lines (HT-29, A549, MDA-MB-231, HeLa and H460), on the basis of the above-described results, the following conclusions could be drawn: (a) most of the prepared compounds displayed the enhanced and selective antitumor activities toward HT-29 and HeLa cell lines as compared with DHA; (b) introduction of bulkier and EWG group on the phenyl ring is associated with increased anti-tumor activity. When the phenyl rings were attached by 4-CF 3 O (9c) or 3-CF 3 (9d), the effect was more obvious; (c) the heteroaryl group at b-position of the enone system may be detrimental for the activity; (d) the configuration of compounds 9a-l, 10a-l at C-10 position has little influence on their anti-tumor activities. Moreover, the two important intermediates 4 and 5 reported firstly also show more potent antitumor activities than DHA. Taking them as intermediates, many novel arteminin derivatives will be obtained and evaluated for their biological activities. To assess the potentials of these new compounds as cancer chemotherapeutic agents, further in vivo activity and toxicity studies are needed. The results obtained from this study can be used as guidelines for further development.
Experimental
Reagents and General Procedures All melting points were obtained on a Büchi Melting Point B-540 apparatus (Büchi Labortechnik, Flawil, Switzerland) and were uncorrected. Mass spectra (MS) were taken in electrospray ionization (ESI) mode on Agilent 1100 LC-MS (Agilent, Palo Alto, CA, U.S.A.). Proton (1H) nuclear magnetic resonance spectroscopy was performed using Bruker ARX-300, 300 MHz spectrometers (Bruker Bioscience, Billerica, MA, U.S.A.) with tetramethylsilane (TMS) as an internal standard. IR spectra (KBr disks) were recorded with a Bruker IFS 55 instrument (Bruker). Elemental analysis was determined on a Carlo-Erba 1106 Elemental analysis instrument (Carlo Erba, Milan, Italy). Unless otherwise 986
Vol. 59, No. 8 noted, all the materials were obtained from commercially available sources and were used without further purification.
Preparation of 10b b-Azidodihydroartemisinin (2), 10a a-Azidodihydroartemisinin (3) Trimethylchlorosilane (300 mmol, 38.1 ml) was added gradually to the mixture solution of dihydroartemisinin (200 mmol, 56.8 g) and sodium azide (300 mmol, 19.5 g) in dry dichloromethane (300 ml), then sodium iodide (5 mmol, 3.0 g) was added to the reaction mixture at 0-5°C. The reaction mixture was stirred at room temperature for 28 h. The mixture was quenched with a saturated NaHCO 3 solution (100 ml) and diluted with dichloromethane. Two phases were separated and the organic phase was washed with brine, the organic phase was then collected and dried overnight over anhydrous Na 2 SO 4 . After filtering, the solvent was evaporated under reduced pressure. The crude mixture was purified by column chromatography (silica, 1-5% EtOAc/hexanes) to furnish the compound 2 (29.0 g, 47%) and compound 3 as white solid (3.0 g, 5%). Preparation of 10b b-Aminodihydroartemisinin (4) A 100 ml roundbottomed flask was charged with compound 2 (16.0 g, 52 mmol) and tetrahydrofuran (THF) (130 ml). To this solution, triphenyl phosphine (20.4 g, 78 mmol) was added slowly, and the reaction mixture was stirred for 2 h at 60°C. At this time, TLC analysis confirmed that no starting material (compound 2) remained. Distilled water (160 mmol, 3.0 ml) was added, and the resulting suspension was stirred for 6 h. The X-ray crystallographic analysis of 5 was determined on a colorless plate crystal, with approximate dimensions of 0.40 mmϫ0.45 mmϫ0.48 mm, grown from the slow evaporation of a dilute ethanol solution at room temperature. The crystal structure solution was solved by full matrix leastsquares method using SHELXL97. All the atoms were located in different Fourier maps and refined isotropically, using a riding model and all the projections were generated using ORTEP. The details of the crystal data and refinement are shown in 
uk).
Preparation of (10R)-N-Chloroacetyl-aminodihydroartemisinin (7) Triethylamine (3.2 g, 31.8 mmol) was added to a solution of compound 4 (6.0 g, 21.2 mmol) in dichloromethane (80 ml) and then 2-chloroacetyl chloride (3.1 g, 27.6 mmol) was added drop-wise to the reaction mixture at 0-10°C. The reaction mixture was stirred at room temperature for 1-3 h. After completion of reaction as indicated by TLC, the mixture was quenched with H 2 O (5 ml) and diluted with dichloromethane (50 ml). The organic layer was washed with brine (200 ml), dried over MgSO 4 , filtered, and concentrated under reduced pressure. The resultant solid products were collected by filtration and recrystallized from methanol to give compound 7 (5.9 g, 78% 
Preparation of (10S)-N-Chloroacetyl-aminodihydroartemisinin (8)
The product was prepared from 4 (3.0 g, 10.6 mmol) in a similar manner as described for the preparation of compound 7. The resultant solid products were collected by filtration and recrystallized from methanol to give compound 8 (3.1 g, 81% General Procedure for Preparation of Compounds (6a-l) A stirred solution of p-hydroxyacetophenone (8.1 g, 0.06 mol) in ethanol (200 ml) was added to 60% KOH (6.7 g, 0.12 mol) solution at 0°C, the mixture was stirred at 0°C temperature for 1 h. The substituted aryl aldehyde (0.06 mol) was added to the mixture, and the resulting mixture was stirred at room temperature for 24 h. The aqueous mixture was neutralized by the addition of aqueous 10% HCl solution. The light yellow solid thus obtained was filtered, washed with water and dried. The residue was recrystallized from ethanol to afford pure compounds (6a-l).
General Procedure for Preparation of Compounds (9a-l), Compounds (10a-l) K 2 CO 3 (0.12 g, 0.84 mmol) and NaI (0.03 g) were added to a stirred solution of compound 7 or compound 8 (0.2 g, 0.57 mmol) and substituted chalcone (0.57 mmol) in DMF (6.0 ml). The reaction mixture was heated to 60°C for 3-5 h. The mixture was poured into ice water, stirred for 1h and separated by filtration to give crude compounds, which purified by chromatography on silica gel using (1-5% petroleum ether/ethyl acetate) to obtain 9a-l, 10a-l. 62 (s, 2H), 3.95 (s, 6H), 3.76 (s, 3H), 2.54-2.30 (m, 2H), 2.13-2.00 (m, 1H), 2.00-1.86 (m, 1H), 1.84-1.70 (m, 2H), 1.45 (s, 3H) Anti-tumor Activity Assay in Vitro The anti-tumor activities of compounds 9a-l and 10a-l were evaluated with HT-29, A549, MDA-MB-231, HeLa, and H460 cell lines by the standard MTT assay in vitro, with DHA as the positive control. The cancer cell lines were cultured in minimum essential medium (MEM) supplement with 10% fetal bovine serum (FBS).
Approximately 4ϫ10 3 cells, suspended in MEM, were plated onto each well of a 96-well plate and incubated in 5% CO 2 at 37°C for 24 h. The test compounds at indicated final concentrations were added to the culture medium and the cell cultures were continued for 72 h. Fresh MTT was added to each well at a terminal concentration of 5 mg/ml and incubated with cells at 37°C for 4 h. The formazan crystals were dissolved in 100 ml dimethyl sulfoxide (DMSO) each well, and the absorbency at 492 nm (for absorbance of MTT formazan) and 630 nm (for the reference wavelength) was measured with the enzyme-linked immunosorbent assay (ELISA) reader. All of the compounds were tested twice in each of the cell lines. The results expressed as IC 50 (inhibitory concentration 50%) were the averages of two determinations and calculated by using the Bacus Laboratories Inc. Slide Scanner (Bliss) software.
